Abstract
BackgroundOsteoarthritis (OA) is a major clinical and public health problem, with no current medications approved as having disease modifying effects. HMG-CoA reductase inhibitors, or “statins”, a drug class widely used to prevent cardiovascular events, could potentially affect OA progression via a number of mechanisms including their effects on lipid metabolism and inflammation. The aim of this multicentre, randomised, double-blind, placebo-controlled trial is to determine whether atorvastatin reduces the progression of knee structural changes and symptoms over 2 years in patients with symptomatic knee OA.Methods/design350 patients with symptomatic knee OA will be recruited through the OA Clinical Trial Network (in Melbourne, Hobart and Adelaide). They will be randomly allocated to the two arms of the study, receiving either 40 mg of atorvastatin or identical placebo once daily for 2 years. Magnetic resonance imaging of the knee will be performed at baseline and 2 years later. Knee structure, symptoms and function will be assessed using validated methods. The primary outcome is annual percentage change in knee cartilage volume. Secondary outcomes include progression of cartilage defects, bone marrow lesions, knee pain and function. The primary analysis will be by intention to treat, but per protocol analyses will also be performed.DiscussionThe study will provide high-quality evidence to address whether atorvastatin has a novel disease modifying effect in OA by delaying the structural and symptomatic progression of knee OA. Thus, the trial has major public health and clinical importance, as if found to be beneficial, atorvastatin could produce substantial cost savings by delaying and possibly reducing the need for joint replacement surgery, and provide marked improvements in quality of life for people with OA.Trial registrationAustralian New Zealand Clinical Trials Registry: ACTRN12613000190707, registered on 18 February 2013.
Highlights
Osteoarthritis (OA) is a major clinical and public health problem, with no current medications approved as having disease modifying effects
In recent longitudinal magnetic resonance imaging (MRI) studies, we showed that higher serum cholesterol and triglyceride levels were associated with adverse structural changes in asymptomatic middle-aged women over 2 years [10], while higher serum levels of high-density lipoprotein (HDL) cholesterol were protective against worsening of bone marrow lesion (BML) in older adults over 2.7 years [11]
We proposed a multicentre, randomised, double-blind, placebo-controlled trial to determine whether atorvastatin has a disease modifying effect in symptomatic knee OA by slowing the structural progression of knee OA and improving knee symptoms
Summary
We proposed a multicentre, randomised, double-blind, placebo-controlled trial to determine whether atorvastatin has a disease modifying effect in symptomatic knee OA by slowing the structural progression of knee OA and improving knee symptoms. Being the most common subchondral bone abnormality described in OA, BMLs are associated with knee pain [65], predict disease progression [66], cartilage volume loss [13] and joint replacement [14] These MRIassessed knee structural changes have been chosen as the primary and secondary outcome measures in this study. This randomised controlled trial will provide high-quality evidence to address whether atorvastatin has a novel disease modifying effect in OA by delaying the structural and symptomatic progression of knee OA. All authors revised the manuscript and gave final approval of the version to be submitted
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
